First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102 (Enzastaurin) in Patients with Newly-Diagnosed Glioblastoma (GBM)
Share this article Share this article SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM). This randomized, double-blind, placebo-controlled global study is to enroll more than 300 patients and the primary outcome measure is overall survival in patients ...
Source: prnewswire.com